{"id":1938,"date":"2024-04-03T15:53:10","date_gmt":"2024-04-03T15:53:10","guid":{"rendered":"https:\/\/stoxpo.com\/?p=1938"},"modified":"2024-04-03T15:53:11","modified_gmt":"2024-04-03T15:53:11","slug":"fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/","title":{"rendered":"Fanapt Receives FDA Approval for Bipolar I Disorder Treatment"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\">Vanda Pharmaceuticals Expands Fanapt Franchise with Novel Indication<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Vanda Pharmaceuticals (VNDA) has announced a significant milestone as the U.S. Food and Drug Administration (FDA) approves Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. This approval marks a substantial expansion of Fanapt&#8217;s utility beyond its previous use in schizophrenia treatment since 2009.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bipolar disorder affects approximately 2.8% of the U.S. adult population, with severe cases impacting 83%. With Fanapt now approved for bipolar I disorder, patients and healthcare providers gain a new treatment option backed by over 100,000 patient years of experience. The approval underscores Vanda&#8217;s commitment to addressing high unmet medical needs and improving patient outcomes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dr. Mihael H. Polymeropoulos, Vanda&#8217;s President, CEO, and Chairman of the Board, emphasized the complexity of manic or mixed episodes associated with bipolar I disorder and the need for trusted treatment options tailored to individual patient needs. The approval of Fanapt represents a pivotal advancement in managing bipolar disorder and reflects Vanda&#8217;s dedication to innovation and patient-centric care.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Read original press release:<a href=\"https:\/\/www.prnewswire.com\/news-releases\/vanda-pharmaceuticals-fanapt-iloperidone-receives-us-fda-approval-for-the-acute-treatment-of-bipolar-i-disorder-302106405.html\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">here<\/mark><\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/amazons-aws-division-implements-layoffs-amidst-shifting-market-dynamics\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Amazon\u2019s AWS Division Implements Layoffs Amidst Shifting Market Dynamics<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vanda Pharmaceuticals Expands Fanapt Franchise with Novel Indication Vanda Pharmaceuticals (VNDA) has announced a significant milestone as the U.S. Food and Drug Administration (FDA) approves Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. This approval marks a substantial expansion of Fanapt&#8217;s utility beyond its [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1430,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"1","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"1","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]},"footnotes":""},"categories":[309,359],"tags":[],"coauthors":[453],"class_list":["post-1938","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceuticals","category-small-cap"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fanapt Receives FDA Approval for Bipolar I Disorder Treatment - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fanapt Receives FDA Approval for Bipolar I Disorder Treatment - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Vanda Pharmaceuticals Expands Fanapt Franchise with Novel Indication Vanda Pharmaceuticals (VNDA) has announced a significant milestone as the U.S. Food and Drug Administration (FDA) approves Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. This approval marks a substantial expansion of Fanapt&#8217;s utility beyond its [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-03T15:53:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-03T15:53:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1706\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Liliana Vida\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Liliana Vida\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/03\\\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/03\\\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\\\/\"},\"author\":{\"name\":\"Liliana Vida\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\"},\"headline\":\"Fanapt Receives FDA Approval for Bipolar I Disorder Treatment\",\"datePublished\":\"2024-04-03T15:53:10+00:00\",\"dateModified\":\"2024-04-03T15:53:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/03\\\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\\\/\"},\"wordCount\":206,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/03\\\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-polina-tankilevitch-3735709-scaled.jpg\",\"articleSection\":[\"Pharmaceuticals\",\"Small-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/03\\\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/03\\\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\\\/\",\"name\":\"Fanapt Receives FDA Approval for Bipolar I Disorder Treatment - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/03\\\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/03\\\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-polina-tankilevitch-3735709-scaled.jpg\",\"datePublished\":\"2024-04-03T15:53:10+00:00\",\"dateModified\":\"2024-04-03T15:53:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/03\\\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/03\\\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/03\\\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-polina-tankilevitch-3735709-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-polina-tankilevitch-3735709-scaled.jpg\",\"width\":2560,\"height\":1706,\"caption\":\"chemistry\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/03\\\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fanapt Receives FDA Approval for Bipolar I Disorder Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\",\"name\":\"Liliana Vida\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"caption\":\"Liliana Vida\"},\"description\":\"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/stoxpo-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fanapt Receives FDA Approval for Bipolar I Disorder Treatment - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Fanapt Receives FDA Approval for Bipolar I Disorder Treatment - Stoxpo","og_description":"Vanda Pharmaceuticals Expands Fanapt Franchise with Novel Indication Vanda Pharmaceuticals (VNDA) has announced a significant milestone as the U.S. Food and Drug Administration (FDA) approves Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. This approval marks a substantial expansion of Fanapt&#8217;s utility beyond its [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/","og_site_name":"Stoxpo","article_published_time":"2024-04-03T15:53:10+00:00","article_modified_time":"2024-04-03T15:53:11+00:00","og_image":[{"width":2560,"height":1706,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg","type":"image\/jpeg"}],"author":"Liliana Vida","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Liliana Vida","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/"},"author":{"name":"Liliana Vida","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1"},"headline":"Fanapt Receives FDA Approval for Bipolar I Disorder Treatment","datePublished":"2024-04-03T15:53:10+00:00","dateModified":"2024-04-03T15:53:11+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/"},"wordCount":206,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg","articleSection":["Pharmaceuticals","Small-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/","url":"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/","name":"Fanapt Receives FDA Approval for Bipolar I Disorder Treatment - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg","datePublished":"2024-04-03T15:53:10+00:00","dateModified":"2024-04-03T15:53:11+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg","width":2560,"height":1706,"caption":"chemistry"},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/03\/fanapt-receives-fda-approval-for-bipolar-i-disorder-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Fanapt Receives FDA Approval for Bipolar I Disorder Treatment"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1","name":"Liliana Vida","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6","url":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","caption":"Liliana Vida"},"description":"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/stoxpo-com\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1938","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=1938"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1938\/revisions"}],"predecessor-version":[{"id":1939,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/1938\/revisions\/1939"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1430"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=1938"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=1938"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=1938"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=1938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}